Nutritional considerations with antiobesity medications
Obesity · 2024-09 · 32 (9) · 1613-1631
DOI: 10.1002/oby.24067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, online erschienen am 10.06.2024. Verfasst von Jaime P Almandoz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence‐based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well‐being and promote optimal nutritional and medical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, Texas, USA.
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Knownwell, Boston, Massachusetts, USA.
- Department of Epidemiology and Prevention and Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Jaime P Almandoz, Thomas A Wadden, Caroline M Apovian, Jamy D Ard, Zhaoping Li, Jesse Richards, W Scott Butsch, Kadie S Vanderman, Lisa M Neff
Förderung
- Eli Lilly and Company
Zitieren
APA
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., Vanderman, K. S., & Neff, L. M. (2024). Nutritional considerations with antiobesity medications. Obesity, 32(9), 1613-1631. https://doi.org/10.1002/oby.24067
Vancouver
Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with antiobesity medications. Obesity. 2024;32(9):1613-1631. doi:10.1002/oby.24067
BibTeX
@article{Almandoz2024,
author = {Almandoz, Jaime P and Wadden, Thomas A and Tewksbury, Colleen and Apovian, Caroline M and Fitch, Angela and Ard, Jamy D and Li, Zhaoping and Richards, Jesse and Butsch, W Scott and Jouravskaya, Irina and Vanderman, Kadie S and Neff, Lisa M},
title = {Nutritional considerations with antiobesity medications},
journal = {Obesity},
year = {2024},
volume = {32},
number = {9},
pages = {1613--1631},
doi = {10.1002/oby.24067}
}
EUVIMED